CVS Health (CVS.US) stock fell 5% despite the fact that the drugstore chain reported upbeat quarterly figures. Company earned $1.30 per share, well above market expectations of $1.24 per share. Revenue came in at $69.55 billion, compared with $68.75 billion expected as prescription volume lifted sales and the drugstore chain attracted new customers with Covid-19 testing and vaccines. However the company warned that the current quarter will be its lowest earnings quarter for the year because of the weaker flu season and investments to its Covid vaccine program.
CVS Health (CVS.US) stock fell sharply after the US open, however sellers failed to break below the upward trendline and price returned to $71.35 level. If buyers will manage to break above it, then another upward impulse towards resistance at $77.29 could be launched. On the other hand, should a break below the aforementioned trendline occur, then downward move could be extended to the $65.70 level. Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
